ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Consolidation nightmare

<< Previous

Bullboard Posts

Next >>

Comment by Thenorth1990on Oct 21, 2021 2:09pm

106 Views

Post# 34033753

RE:RE:RE:Consolidation nightmare

I think being too close to the min bid price might not being a good idea. I was thinking 20 to 1.. but this is brutal. The only benefit I see(short term) small floats in Nasdaq goes 100% to 300% on a pr. Not sustainable, but still. So if they are planning to open up their mouth about serolgy after nasdaq listing in 2022 may be its good for us.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property